Result in these studies demonstrate that combined low-dose treatment of γ-tocotrienol and PPARγ antagonists act synergistically to inhibit human breast cancer cell proliferation, and this effect appears to be mediated by a large reduction in PPARγ expression and corresponding reduction in PI3K/Akt mitogenic signaling. This evidence concerns the gene PPARG and breast cancer.